Related Experiment Video
Updated: Jul 5, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Longitudinal decline in autopsy-defined frontotemporal lobar degeneration
M Grossman1, S X Xie, D J Libon
1Department of Neurology, University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104-4283, USA. mgrossma@mail.med.upenn.edu
Neurology
|April 19, 2008
Summary
Frontotemporal lobar degeneration (FTLD) patients show significant cognitive decline over time. Specific neuropsychological tests can differentiate between tau-positive FTLD, tau-negative FTLD, and frontal variant-Alzheimer disease (fvAD) subgroups.
Area of Science:
- Neuroscience
- Neuropathology
- Cognitive Neurology
Background:
- The natural history of frontotemporal lobar degeneration (FTLD) is crucial for clinical and biological understanding but lacks quantitative documentation.
- Accurate characterization of FTLD subtypes and their progression is essential for effective patient management.
Purpose of the Study:
- To quantitatively examine longitudinal cognitive decline in pathologically proven FTLD cohorts.
- To identify neuropsychological measures that differentiate between histopathologically distinct FTLD subgroups.
Main Methods:
- Analysis of longitudinal cognitive functioning using neuropsychological measures in an autopsy-proven cohort.
- Categorization of patients into tau-positive FTLD, tau-negative FTLD, and frontal variant-Alzheimer disease (fvAD) subgroups based on autopsy findings.
Main Results:
- Significant longitudinal decline observed across all neuropsychological measures.
- Specific measures, like visual construction and confrontation naming, differentiated between tau-positive and tau-negative FTLD.
- Naming fluency measures distinguished FTLD subgroups from fvAD patients.
Conclusions:
- Distinct longitudinal cognitive decline patterns exist in pathologically defined FTLD subgroups.
- Measures differentiating subgroups can enhance diagnostic accuracy.
- Measures showing undifferentiated decline may serve as endpoints in treatment trials.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:05Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
01:03Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...